DBV Technologies SA – (NASDAQ:DBVT)’s share price rose 3.7% during trading on Tuesday . The company traded as high as $35.35 and last traded at $35.07, with a volume of 65,772 shares traded. The stock had previously closed at $33.83.

DBVT has been the topic of a number of analyst reports. Zacks Investment Research raised shares of DBV Technologies SA – from a “sell” rating to a “hold” rating in a research note on Tuesday, August 2nd. Jefferies Group reaffirmed a “buy” rating on shares of DBV Technologies SA – in a research note on Wednesday, June 8th. One equities research analyst has rated the stock with a hold rating, seven have given a buy rating and one has assigned a strong buy rating to the company. The stock presently has an average rating of “Buy” and a consensus price target of $50.52.

The company’s market cap is $1.56 billion. The stock’s 50 day moving average price is $33.84 and its 200-day moving average price is $31.31.

Several institutional investors recently made changes to their positions in DBVT. Jennison Associates LLC increased its position in shares of DBV Technologies SA – by 0.9% in the fourth quarter. Jennison Associates LLC now owns 721,775 shares of the company’s stock worth $26,208,000 after buying an additional 6,578 shares in the last quarter. RS Investment Management Co. LLC boosted its stake in shares of DBV Technologies SA – by 1.7% in the fourth quarter. RS Investment Management Co. LLC now owns 502,860 shares of the company’s stock worth $18,259,000 after buying an additional 8,220 shares during the last quarter. Finally, New York State Common Retirement Fund acquired a new stake in shares of DBV Technologies SA – during the fourth quarter worth approximately $2,551,000.

DBV Technologies SA is a France-based clinical-stage biopharmaceutical company focused on changing the field of immunotherapy by developing a technology platform called Vaskin. The Company’s therapeutic approach is based on epicutaneous immunotherapy, or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.